BlossomHill Takes Aim at Cancer Resistance at J.P. Morgan Conference

SAN DIEGO, CA – January 05, 2026 – BlossomHill Therapeutics, a privately-held clinical-stage biopharmaceutical company, is poised for a pivotal moment as it prepares to present at the 44th Annual J.P. Morgan Healthcare Conference. The San Diego-based firm announced that its President and CEO, J. Jean Cui, Ph.D., and Chief Medical Officer, Geoff Oxnard, M.D., will take the stage on Monday, January 12, to outline the company's next-generation oncology pipeline.

The presentation is set to draw significant attention from investors and industry leaders, offering a detailed look at two highly anticipated cancer therapies designed to tackle some of the most persistent challenges in modern oncology: drug resistance and difficult-to-treat hematologic malignancies.

JPM Spotlight: A Strategic Play for a Biotech on the Rise

The J.P. Morgan Healthcare Conference is widely regarded as the premier event in the biopharmaceutical industry, a venue where corporate strategy, scientific innovation, and high-stakes investment converge. For a clinical-stage company like BlossomHill, this presentation is far more than a simple pipeline update; it is a strategic maneuver on the industry's biggest stage.

Having already secured an impressive $257 million in funding from leading life sciences investors, BlossomHill is operating from a position of financial strength. This substantial backing signals strong early confidence in its science and leadership. However, in a market where investors have become increasingly selective, a compelling performance at JPM is crucial. Today's investors are prioritizing companies with experienced management, de-risked clinical assets, and a clear path forward—criteria that BlossomHill appears well-positioned to meet.

The timing is also opportune. The biopharma sector has seen a resurgence in merger and acquisition (M&A) activity, with large pharmaceutical giants actively scouting for innovative assets to replenish their pipelines. A company with a promising, de-risked oncology portfolio could become a prime target for partnership or acquisition. The presentation will serve as a critical platform to broadcast the company’s progress, potentially attracting further investment to fuel its ambitious clinical programs or setting the stage for a future initial public offering (IPO).

A New Generation of Cancer Weapons in the Clinic

At the heart of the anticipation surrounding BlossomHill are its two lead clinical candidates, BH-30643 and BH-30236, each employing a novel scientific approach to address significant unmet medical needs.

BH-30643: A Multi-Pronged Attack on Lung Cancer

BlossomHill's lead asset, BH-30643, is being evaluated in a Phase 1/2 trial for non-small cell lung cancer (NSCLC) driven by EGFR mutations. While targeted therapies like osimertinib (Tagrisso) have transformed outcomes for these patients, the inevitable development of drug resistance remains a formidable obstacle. BlossomHill describes BH-30643 as a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFR™ inhibitor.

This designation points to a highly differentiated strategy. The "OMNI-EGFR™" name suggests the drug is designed to inhibit a broad spectrum of cancer-driving EGFR mutations, including those that confer resistance to current third-generation inhibitors. Its macrocyclic chemical structure may offer superior drug-like properties, while its mutant-selective nature aims to potently target cancer cells while sparing healthy ones, potentially leading to a better safety profile. Crucially, its CNS-active property means it is designed to cross the blood-brain barrier, a critical feature for treating or preventing brain metastases, a common and devastating complication of EGFR-mutant lung cancer.

If the SOLARA trial data demonstrates success, BH-30643 could represent a significant advancement, offering a new line of defense for patients whose disease has progressed on current standards of care.

BH-30236: Targeting the Machinery of Blood Cancers

Equally innovative is BH-30236, a novel macrocyclic CLK inhibitor targeting aberrant RNA splicing. This candidate is being developed for patients with relapsed or refractory acute myeloid leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS)—two aggressive blood cancers with dire prognoses and limited effective treatment options.

Instead of targeting a single mutated protein, BH-30236 targets the fundamental cellular machinery of RNA splicing. In many cancers, this process becomes dysregulated, leading to the production of abnormal proteins that fuel cancer growth and survival. By inhibiting a key regulator of this process, the CLK kinase family, BH-30236 aims to disrupt the cancer cell's ability to produce these oncogenic proteins. This first-in-class mechanism represents a completely new therapeutic avenue for AML and MDS, offering hope for patients who have exhausted existing therapies like chemotherapy or other targeted agents.

The Visionaries Behind the Science

In the high-risk world of biotechnology, a company's leadership is as critical as its science. BlossomHill is helmed by a team whose credentials command respect throughout the industry.

Founder and CEO J. Jean Cui, Ph.D., is a drug discovery luminary. Her legacy is already cemented by her pivotal role in the invention of two FDA-approved, blockbuster cancer drugs during her time at Pfizer: crizotinib (Xalkori) and lorlatinib (Lorbrena). Both drugs revolutionized the treatment of ALK-positive NSCLC, establishing new standards of care and generating billions in revenue. Her decision to found BlossomHill and pursue a new generation of targeted therapies is a powerful endorsement of the company's underlying science.

Complementing her discovery expertise is Chief Medical Officer Geoff Oxnard, M.D., an internationally recognized thoracic oncologist and clinical expert in EGFR-mutant lung cancer and drug resistance. His deep clinical insight is invaluable for guiding the development of BH-30643 and ensuring its design addresses the most critical challenges faced by patients and clinicians. The combination of Dr. Cui's proven drug design prowess and Dr. Oxnard's clinical development acumen creates a leadership team uniquely equipped to navigate the complexities of oncology drug development.

As BlossomHill Therapeutics steps into the spotlight at the J.P. Morgan conference, it brings more than just promising molecules. It brings a seasoned leadership team, substantial financial backing, and a clear strategy to tackle some of cancer's most intractable problems. The presentation will be closely watched as a bellwether for the company's future and its potential to deliver the next wave of life-changing cancer medicines. For patients and investors alike, the data that follows this high-profile presentation will be the ultimate measure of the company's ambitious vision.